Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.
Combined radiochemotherapy is the currently used therapy for locally advanced pancreatic ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application. Here we test the hypothesis that inhibition of ATR (ATM-Rad3-related) could increase the sensitivity of the cancer cells to radiat...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Nature Publishing Group:
2012
|
| _version_ | 1826301496133681152 |
|---|---|
| author | Fokas, E Prevo, R Pollard, J Reaper, P Charlton, P Cornelissen, B Vallis, K Hammond, E Olcina, M Gillies McKenna, W Muschel, R Brunner, T |
| author_facet | Fokas, E Prevo, R Pollard, J Reaper, P Charlton, P Cornelissen, B Vallis, K Hammond, E Olcina, M Gillies McKenna, W Muschel, R Brunner, T |
| author_sort | Fokas, E |
| collection | OXFORD |
| description | Combined radiochemotherapy is the currently used therapy for locally advanced pancreatic ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application. Here we test the hypothesis that inhibition of ATR (ATM-Rad3-related) could increase the sensitivity of the cancer cells to radiation or chemotherapy without affecting normal cells. We tested VE-822, an ATR inhibitor, for in vitro and in vivo radiosensitization. Chk1 phosphorylation was used to indicate ATR activity, γH2AX and 53BP1 foci as evidence of DNA damage and Rad51 foci for homologous recombination activity. Sensitivity to radiation (XRT) and gemcitabine was measured with clonogenic assays in vitro and tumor growth delay in vivo. Murine intestinal damage was evaluated after abdominal XRT. VE-822 inhibited ATR in vitro and in vivo. VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells. VE-822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine. VE-822 markedly prolonged growth delay of pancreatic cancer xenografts after XRT and gemcitabine-based chemoradiation without augmenting normal cell or tissue toxicity. These findings support ATR inhibition as a promising new approach to improve the therapeutic ration of radiochemotherapy for patients with PDAC. |
| first_indexed | 2024-03-07T05:33:18Z |
| format | Journal article |
| id | oxford-uuid:e3033215-ee1a-4b8f-b91b-1ba8b6ba8250 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:33:18Z |
| publishDate | 2012 |
| publisher | Nature Publishing Group: |
| record_format | dspace |
| spelling | oxford-uuid:e3033215-ee1a-4b8f-b91b-1ba8b6ba82502022-03-27T10:05:57ZTargeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e3033215-ee1a-4b8f-b91b-1ba8b6ba8250EnglishSymplectic Elements at OxfordNature Publishing Group:2012Fokas, EPrevo, RPollard, JReaper, PCharlton, PCornelissen, BVallis, KHammond, EOlcina, MGillies McKenna, WMuschel, RBrunner, TCombined radiochemotherapy is the currently used therapy for locally advanced pancreatic ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application. Here we test the hypothesis that inhibition of ATR (ATM-Rad3-related) could increase the sensitivity of the cancer cells to radiation or chemotherapy without affecting normal cells. We tested VE-822, an ATR inhibitor, for in vitro and in vivo radiosensitization. Chk1 phosphorylation was used to indicate ATR activity, γH2AX and 53BP1 foci as evidence of DNA damage and Rad51 foci for homologous recombination activity. Sensitivity to radiation (XRT) and gemcitabine was measured with clonogenic assays in vitro and tumor growth delay in vivo. Murine intestinal damage was evaluated after abdominal XRT. VE-822 inhibited ATR in vitro and in vivo. VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells. VE-822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine. VE-822 markedly prolonged growth delay of pancreatic cancer xenografts after XRT and gemcitabine-based chemoradiation without augmenting normal cell or tissue toxicity. These findings support ATR inhibition as a promising new approach to improve the therapeutic ration of radiochemotherapy for patients with PDAC. |
| spellingShingle | Fokas, E Prevo, R Pollard, J Reaper, P Charlton, P Cornelissen, B Vallis, K Hammond, E Olcina, M Gillies McKenna, W Muschel, R Brunner, T Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. |
| title | Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. |
| title_full | Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. |
| title_fullStr | Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. |
| title_full_unstemmed | Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. |
| title_short | Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. |
| title_sort | targeting atr in vivo using the novel inhibitor ve 822 results in selective sensitization of pancreatic tumors to radiation |
| work_keys_str_mv | AT fokase targetingatrinvivousingthenovelinhibitorve822resultsinselectivesensitizationofpancreatictumorstoradiation AT prevor targetingatrinvivousingthenovelinhibitorve822resultsinselectivesensitizationofpancreatictumorstoradiation AT pollardj targetingatrinvivousingthenovelinhibitorve822resultsinselectivesensitizationofpancreatictumorstoradiation AT reaperp targetingatrinvivousingthenovelinhibitorve822resultsinselectivesensitizationofpancreatictumorstoradiation AT charltonp targetingatrinvivousingthenovelinhibitorve822resultsinselectivesensitizationofpancreatictumorstoradiation AT cornelissenb targetingatrinvivousingthenovelinhibitorve822resultsinselectivesensitizationofpancreatictumorstoradiation AT vallisk targetingatrinvivousingthenovelinhibitorve822resultsinselectivesensitizationofpancreatictumorstoradiation AT hammonde targetingatrinvivousingthenovelinhibitorve822resultsinselectivesensitizationofpancreatictumorstoradiation AT olcinam targetingatrinvivousingthenovelinhibitorve822resultsinselectivesensitizationofpancreatictumorstoradiation AT gilliesmckennaw targetingatrinvivousingthenovelinhibitorve822resultsinselectivesensitizationofpancreatictumorstoradiation AT muschelr targetingatrinvivousingthenovelinhibitorve822resultsinselectivesensitizationofpancreatictumorstoradiation AT brunnert targetingatrinvivousingthenovelinhibitorve822resultsinselectivesensitizationofpancreatictumorstoradiation |